Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1991 Aug;50(8):562–566. doi: 10.1136/ard.50.8.562

High molecular weight glycosaminoglycans in AA type amyloid fibril extracts from human liver.

J H Magnus 1, S O Kolset 1, G Husby 1
PMCID: PMC1004488  PMID: 1888198

Abstract

Glycosaminoglycans have previously been identified in extracts of AA type hepatic amyloid fibril from a patient with amyloidosis associated with juvenile rheumatoid arthritis. The macromolecular properties of these polysaccharides are described here in more detail. By gel filtration and ion exchange chromatography glycosaminoglycans in the form of high molecular weight free chains were shown to coisolate with water extracted amyloid fibrils. About 60% of these were characterised as galactosamines (chondroitin sulphate/dermatan sulphate), whereas the remaining 40% consisted of N-sulphated glucosamines (heparin/heparan sulphate). The amyloid associated glycosaminoglycans were not part of intact proteoglycans in the fibril extracts.

Full text

PDF
562

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BITTER T., MUIR H. M. A modified uronic acid carbazole reaction. Anal Biochem. 1962 Oct;4:330–334. doi: 10.1016/0003-2697(62)90095-7. [DOI] [PubMed] [Google Scholar]
  2. Benditt E. P., Eriksen N., Hermodson M. A., Ericsson L. H. The major proteins of human and monkey amyloid substance: Common properties including unusual N-terminal amino acid sequences. FEBS Lett. 1971 Dec 1;19(2):169–173. doi: 10.1016/0014-5793(71)80506-9. [DOI] [PubMed] [Google Scholar]
  3. Bitter T., Muir H. Mucopolysaccharides of whole human spleens in generalized amyloidosis. J Clin Invest. 1966 Jun;45(6):963–975. doi: 10.1172/JCI105412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen A. S., Connors L. H. The pathogenesis and biochemistry of amyloidosis. J Pathol. 1987 Jan;151(1):1–10. doi: 10.1002/path.1711510102. [DOI] [PubMed] [Google Scholar]
  5. Glenner G. G. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. 1980 Jun 5;302(23):1283–1292. doi: 10.1056/NEJM198006053022305. [DOI] [PubMed] [Google Scholar]
  6. Hamazaki H. Ca2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. J Biol Chem. 1987 Feb 5;262(4):1456–1460. [PubMed] [Google Scholar]
  7. Harada M., Isersky C., Cuatrecasas P., Page D., Bladen H. A., Eanes E. D., Keiser H. R., Glenner G. G. Human amyloid protein: chemical variability and homogeneity. J Histochem Cytochem. 1971 Jan;19(1):1–15. doi: 10.1177/19.1.1. [DOI] [PubMed] [Google Scholar]
  8. Heinegård D., Sommarin Y. Isolation and characterization of proteoglycans. Methods Enzymol. 1987;144:319–372. doi: 10.1016/0076-6879(87)44186-4. [DOI] [PubMed] [Google Scholar]
  9. Holck M., Husby G., Sletten K., Natvig J. B. The amyloid P-component (protein AP): an integral part of the amyloid substance? Scand J Immunol. 1979;10(1):55–60. doi: 10.1111/j.1365-3083.1979.tb01334.x. [DOI] [PubMed] [Google Scholar]
  10. Husby G., Sletten K. Chemical and clinical classification of amyloidosis 1985. Scand J Immunol. 1986 Mar;23(3):253–265. doi: 10.1111/j.1365-3083.1986.tb01966.x. [DOI] [PubMed] [Google Scholar]
  11. Husby G., Sletten K., Michaelsen T. E., Natvig J. B. Amyloid fibril protein subunit, "protein AS": distribution in tissue and serum in different clinical types of amyloidosis including that associated with myelomatosis and Waldenström's macroglobulinamia. Scand J Immunol. 1973;2(4):395–404. doi: 10.1111/j.1365-3083.1973.tb02048.x. [DOI] [PubMed] [Google Scholar]
  12. Husby G., Sletten K. Structural similarities between a protein extracted from normal human tissues and a component of amyloid fibrils. Acta Pathol Microbiol Scand C. 1977 Jun;85(3):153–160. doi: 10.1111/j.1699-0463.1977.tb03625.x. [DOI] [PubMed] [Google Scholar]
  13. Kawahara E., Shiroo M., Nakanishi I., Migita S. The role of fibronectin in the development of experimental amyloidosis. Evidence of immunohistochemical codistribution and binding property with serum amyloid protein A. Am J Pathol. 1989 Jun;134(6):1305–1314. [PMC free article] [PubMed] [Google Scholar]
  14. Kisilevsky R., Snow A. The potential significance of sulphated glycosaminoglycans as a common constituent of all amyloids: or, perhaps amyloid is not a misnomer. Med Hypotheses. 1988 Aug;26(4):231–236. doi: 10.1016/0306-9877(88)90125-9. [DOI] [PubMed] [Google Scholar]
  15. Magnus J. H., Husby G., Kolset S. O. Presence of glycosaminoglycans in purified AA type amyloid fibrils associated with juvenile rheumatoid arthritis. Ann Rheum Dis. 1989 Mar;48(3):215–219. doi: 10.1136/ard.48.3.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Norling B., Westermark G. T., Westermark P. Immunohistochemical identification of heparan sulphate proteoglycan in secondary systemic amyloidosis. Clin Exp Immunol. 1988 Aug;73(2):333–337. [PMC free article] [PubMed] [Google Scholar]
  17. Pepys M. B. Amyloidosis: some recent developments. Q J Med. 1988 Apr;67(252):283–298. [PubMed] [Google Scholar]
  18. Pras M., Schubert M., Zucker-Franklin D., Rimon A., Franklin E. C. The characterization of soluble amyloid prepared in water. J Clin Invest. 1968 Apr;47(4):924–933. doi: 10.1172/JCI105784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Saito H., Yamagata T., Suzuki S. Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates. J Biol Chem. 1968 Apr 10;243(7):1536–1542. [PubMed] [Google Scholar]
  20. Scott D. L., Marhaug G., Husby G. Comparative studies of the high molecular weight amyloid fibril proteins and similar components from normal tissues. Clin Exp Immunol. 1983 Jun;52(3):693–701. [PMC free article] [PubMed] [Google Scholar]
  21. Skinner M., Shirahama T., Cohen A. S., Deal C. L. The association of amyloid P-component (AP) with the amyloid fibril: an updated method for amyloid fibril protein isolation. Prep Biochem. 1982;12(5):461–476. doi: 10.1080/10826068208070597. [DOI] [PubMed] [Google Scholar]
  22. Snow A. D., Kisilevsky R., Stephens C., Anastassiades T. Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Qualitative and quantitative analysis. Lab Invest. 1987 Jun;56(6):665–675. [PubMed] [Google Scholar]
  23. Snow A. D., Kisilevsky R. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study. Lab Invest. 1985 Jul;53(1):37–44. [PubMed] [Google Scholar]
  24. Snow A. D., Willmer J., Kisilevsky R. A close ultrastructural relationship between sulfated proteoglycans and AA amyloid fibrils. Lab Invest. 1987 Dec;57(6):687–698. [PubMed] [Google Scholar]
  25. Snow A. D., Willmer J., Kisilevsky R. Sulfated glycosaminoglycans: a common constituent of all amyloids? Lab Invest. 1987 Jan;56(1):120–123. [PubMed] [Google Scholar]
  26. Vogel K. G., Trotter J. A. The effect of proteoglycans on the morphology of collagen fibrils formed in vitro. Coll Relat Res. 1987 Jun;7(2):105–114. doi: 10.1016/s0174-173x(87)80002-x. [DOI] [PubMed] [Google Scholar]
  27. Wasteson A. A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate. J Chromatogr. 1971 Jul 8;59(1):87–97. doi: 10.1016/s0021-9673(01)80009-1. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES